Icotinib ( DrugBank: Icotinib )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 34 | Neurofibromatosis | 1 |
34. Neurofibromatosis
Clinical trials : 137 / Drugs : 213 - (DrugBank : 76) / Drug target genes : 87 - Drug target pathways : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02934256 (ClinicalTrials.gov) | July 2016 | 13/10/2016 | Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors | Icotinib Hydrochloride Tablets Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors | Vestibular Schwannoma;Neurofibromatosis Type 2 | Drug: Icotinib | Li Peng | Betta Pharmaceuticals Co., Ltd. | Completed | 16 Years | 50 Years | All | 10 | Phase 2 | China |